Shares of Australia's Mayne Pharma are on the rise following hot rumors that it's about to become the subject of a takeover bid. Two generic drug outfits, Hospira and Teva, have been suggested as possible bidders. But other analysts are speculating that the rumors are being triggered by a possible bid by Mayne for another company. Spun out last year from the Mayne Group, Mayne Pharma has been posting losses while boasting of its new drug candidates.
- here's the report on Mayne from The Australian
PLUS: One report suggests that $1.5 billion is being offered for Mayne. Report
ALSO: Mayne Pharma CEO Thierry Soursac has earned $3.8 million since the spin-off. Report